CTOs on the Move

BioSig Technologies

www.biosigtech.com

 
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.biosigtech.com
  • 8441 Wayzata Blvd Ste 240
    Minneapolis, MN USA 55426
  • Phone: 763.999.7330

Executives

Name Title Contact Details

Similar Companies

Johnson and Johnson Visioncare

Johnson and Johnson Vision Care is a company committed to transforming the world's vision. Since our inception, we have strived to increase awareness of the importance of vision and vision care and to provide the world's most exceptional vision correction

Technogym

Technogym is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meridia Audience Response Services

Meridia Audience Response Services is a Plymouth Meeting, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

Accovion

Accovion Inc. is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.